Retina Health Companies

Spark Therapeutics Received FDA approval for Luxturna®, the first gene therapy for Leber's hereditary optic neuropathy (LHON), offering a potential cure for this previously untreatable retinal disease.

Regenxbio Announced positive Phase 3 results for RGX-314 for wet age-related macular degeneration (AMD), demonstrating its potential to significantly improve vision compared to existing treatment options.

MeiraGTX Initiated Phase 2b clinical trial for their MGTX110 gene therapy for diabetic retinopathy, aiming to offer a long-lasting treatment option for this common complication.

DeepMind Developed an AI algorithm that can detect diabetic retinopathy with high accuracy on retinal fundus photographs, potentially enhancing early diagnosis and preventing vision loss.

Iridex Corporation Launched the Iridex IRIDY™ AI platform, providing AI-powered analysis of retinal images to support diagnostic decision-making for various retinal diseases.

Optos Introduced its OCT Angiography (OCTA) Scout module with AI-powered segmentation and vessel analysis, aiding in early detection and monitoring of neovascularization in retinal diseases.

Roche Received FDA approval for Vabysmo® (faricimab), a bivalent VEGF inhibitor for wet AMD, offering extended dosing intervals and potentially reducing treatment burden.

Santen Pharmaceuticals Entered into a collaboration with Bayer AG to develop and commercialize novel gene therapies for retinal diseases, expanding its portfolio and market reach.

Novartis Announced plans to build a new retinal gene therapy manufacturing facility in Switzerland, indicating its commitment to this growing market segment.

• Novartis AG


• Spark Therapeutics


• Gensight Biologics


• Allergan Plc


• Oxford Biomedica Plc


• Hemera Biosciences LLC


• Santen Pharmaceuticals Inc


• Regenxbio Inc


• Meiragtx Limited